Bright Light Therapy on Sleep Health in Lung Cancer Patients

Henry Ford Health System20 enrolled

Overview

The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are: * Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients? * Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging. Participants will: * Receive bright light exposure or usual light exposure every day for 4 weeks * Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests * Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks * Keep a daily sleep log

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Lung Cancers

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \>=18 years of age * Stage Ib to IIIb primary lung cancer diagnosis * \>=2 months after completion of primary therapy, patient can continue to be on maintenance/immunotherapy * ECOG performance status is 0 or 1 * Experience problematic sleep (scores of \>=8 on the Insomnia Severity Index) * Able to understand, speak, and read English * Sighted and mentally competent to consent Exclusion Criteria: * Pregnant women * Have metastatic cancer * on oxygen therapy * Current diagnosis of seasonal affective disorder or substance abuse * Engage in shift work or travel across \>3 time zones within 2 weeks prior to the study * Are currently being treated for sleep apnea, restless legs syndrome, or narcolepsy * Take prescribed sedative hypnotics or antipsychotics * Have eye conditions (glaucoma or retinal disease), problem triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents) * Participants with an Insomnia Severity Index \<8 * Participants with cognitive impairment (sores of \<3 mini-cog test)

Outcomes

Primary Outcomes

Change from Baseline in sleep patterns at 4 weeks

Changes in sleep patterns will be assessed by sleep efficiency (e.g., duration of sleep in hours), sleep quality (e.g., number of sleep disturbance), and sleep onset latency (e.g., minutes of falling asleep).

Time frame: from enrollment to the end of the intervention at 4 weeks

Changes from baseline in the measures of biological age at 4 weeks

Participants have a lower rate of biological aging

Time frame: From enrollment to the end of intervention at 4 weeks

Secondary Outcomes

Change from Baseline in the measure of fatigue and stress at 4 weeks

Participants will achieve a response if they have lower level of fatigue and stress level at 4 weeks. Stress will be assessed by stress scale ranging from 0 to 40, and a higher score refers to worse stress level. Fatigue will be assessed by a fatigue score ranging from 0-40, and a higher scale means severe fatigue level.